Database

Startups

Main Industry
Biotechnology
Main Product/Service
1. LifeOS Developed Assay Panels
2. Assay Co-Development
3. QLoci™ NIPT Assay Panel
4. Maximize your utility on the QLoci™ system.
Founded Year
2015
Unified Business No.
24859657
Status
Active
Number of Employees
0
Total Paid-in Capital
34,833,900 (NT$)
Location of Company
Taiwan , Hsinchu County
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
LifeOS Genomics is a biotechnology and in-vitro diagnostics company focused on IVD genetic testing using liquid biopsy. LifeOS Genomic’s flagship product, the QLoci System, is an automated genetic testing platform based on our novel multiplex digital PCR technology (mdPCR). By leveraging the unique high multiplexity and sensitivity of this PCR technology, LifeOS aims to decentralize and enable the routine practice genetic testing.

Founder Timothy Liu, Ph.D., assembled a team of experts in genetics, chemistry, automation, optics, and medical software to design and develop a medical device that focuses on the IVD experience. LifeOS is positioning the mdPCR platform as a testing solution for a myriad of genetic diseases, with promising applications in non-invasive prenatal testing, early cancer screening, companion diagnostics, infectious disease monitoring, and other areas requiring high multiplexity and high sensitivity.





More ↓

Similar Companies

Rephlmmune Biotechnology Inc.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and

Genicore Biotech CO., LTD.

1. Proprietary Aptamer Screening & Design Technology:
Provides antibody-alternative solutions based on unique nucleic acid selection and design capabilities.

2. Precision Diagnostics Development:
Focused on early cancer detection applications using high-specificity aptamer technologies.

3. Biomarker Analysis Services:
Delivers highly accurate testing and analytical results for biomedical research and diagnostics.

4. Customized Solutions:
Offers tailored development services, integrated biomedical testing technologies, and R&D and manufacturing of innovative diagnostic products.